Eli Lilly Reports Strong Q4 2025 Earnings Driven by Obesity and Diabetes Drugs

Eli Lilly reported strong fourth-quarter 2025 earnings, supported by robust demand for its obesity and diabetes treatments. Revenue growth was led by continued uptake of weight-loss and GLP-1 drugs, while margins improved due to higher volumes. The company reiterated confidence in its growth outlook, citing expanding manufacturing capacity and sustained global demand for its key therapies.